News

NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as showed in a range of in vitro/in vivo assays and human clinical trials. Blockade of CRF receptors at

The IMI grant will be used to accelerate the development and testing of JNJ’s vaccine regimen through a newly formed consortium that includes Janssen, the London School of

Speaking ahead of the eyeforpharma Barcelona 2015 conference, Alberto Grua, CCO at Grünenthalechoed similar industry commitments to putting patient’s needs to the forefront of their decision making, and

The Phase II results showed that mipsagargin appears to be effective and is well-tolerated by HCC patients. Mipsagargin targets the enzyme prostate-specific membrane antigen (PSMA), which is highly

The company said that advancement to the predictive biomarker expansion stage triggered a $5m milestone from its partner GlaxoSmithKline (GSK). The expansion stage of the anti-Notch1 Phase Ia

The deal is expected to strengthen Sanofi’s manufacturing capacity to support upcoming product launches. Currently, 72% of Sanofi’s research and development (R&D) projects are in biologics, nearly half

A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals

CBD or Cannabidiol has been at the forefront of the news lately in its application to treat pediatric epilepsy, autism, cancer, pain, PTSD, brain injuries, anxiety, and various

With the construction of WCCT Global’s influenza challenge facility in Costa Mesa, California, the CRO has the capability to conduct virus challenge clinical trials in North America. WCCT